Syncardia

1 known investors

SynCardia develops the SynCardia Total Artificial Heart (STAH), an FDA-approved device that replaces both failing ventricles to restore blood flow as a bridge to heart transplant. It serves transplant-eligible patients with end-stage biventricular heart failure and the physicians and hospitals treating them.